Non-small cell lung cancer genomics around the globe: focus on ethnicity

Araujo, Luiz H.; Carbone, David P.

doi:10.21037/jtd.2017.03.143

Cited by 4 publications

(5 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Carcinogenesis of NSCLC involves in multistep process which is regulated by activating oncogenes or inactivating tumor-suppressing genes (5). Recently, several microRNAs (miRNAs) have been reported to participate in tumorigenesis of NSCLC which play a carcinogenic or suppressive role in the progression of NSCLC.…”

Section: Introductionmentioning

confidence: 99%

MicroRNA-545 targets ZEB2 to inhibit the development of non‑small cell lung cancer by inactivating Wnt/β-catenin pathway

Cui

Pan

et al. 2019

Oncol Lett

View full text Add to dashboard Cite

The specific function of microRNA-545 (miR-545) has been reported to regulate the development of human cancers. However, the effect of miR-545 is still unclear in non-small cell lung cancer (NSCLC). Hence, this study explored the molecular mechanism of miR-545 in NSCLC. The expression levels of miR-545 and ZEB2 were measured through reverse transcription-quantitative polymerase chain reaction (RT-qPCR) assay. The protein expression was detected by western blotting. Dual luciferase assay was applied to evaluate the relationship between miR-545 and zinc finger E-box-binding homeobox 2 (ZEB2). MTT and Transwell assays were used to investigate the function of miR-545 in NSCLC. The expression of miR-545 was decreased in NSCLC tissues. The overexpression of miR-545 suppressed the migration, invasion and proliferation of NSCLC cells. Furthermore, ZEB2 was a direct target gene of miR-545. The knockout of ZEB2 suppressed the development of NSCLC. miR-545 inhibited the progression of NSCLC through targeting ZEB2. Moreover, miR-545 repressed the development of NSCLC via blocking EMT and Wnt/β-catenin pathway. In conclusion, miR-545 inhibited the progression of NSCLC through targeting ZEB2 and blocking EMT and Wnt/β-catenin pathway.

show abstract

Section: Introductionmentioning

confidence: 99%

MicroRNA-545 targets ZEB2 to inhibit the development of non‑small cell lung cancer by inactivating Wnt/β-catenin pathway

Cui

Pan

et al. 2019

Oncol Lett

View full text Add to dashboard Cite

show abstract

“…Recent evidence supports the association between patient ethnicity and NSCLC features (Refs 68, 69, 70), suggesting that both racial and environmental factors may drive cancer molecular alterations, and justify its heterogeneous clinical evolution.…”

Section: Analysis Of Literature Datamentioning

confidence: 86%

Pulmonary enteric adenocarcinoma: an overview

Palmirotta

Lovero

D’Oronzo

et al. 2020

Expert Rev. Mol. Med.

View full text Add to dashboard Cite

Most commonly described as sporadic, pulmonary adenocarcinoma with enteric differentiation (PAED) is a rare variant of invasive lung cancer recently established and recognised by the World Health Organization. This tumour is highly heterogeneous and shares several morphological features with pulmonary and colorectal adenocarcinomas. Our objective is to summarise current research on PAED, focusing on its immunohistochemical and molecular features as potential tools for differential diagnosis from colorectal cancer, as well as prognosis definition and therapeutic choice. PAED exhibits an ‘entero-like’ pathological morphology in more than half cases, expressing at least one of the typical immunohistochemical markers of enteric differentiation, namely CDX2, CK20 or MUC2. For this reason, this malignancy appears often indistinguishable from a colorectal cancer metastasis, making the differential diagnosis laborious. Although standard diagnostic criteria have not been established yet, in the past few years, a number of approaches have been addressed, aimed at defining specific immunohistochemical and molecular signatures. Based on previously published literature, we have collected and analysed molecular and immunohistochemical data on this rare neoplasm, and have described the state of the art on diagnostic criteria as well as major clinical and therapeutic implications. The analysis of data from 295 patients from 58 published articles allowed us to identify the most represented immunohistochemical and molecular markers, as well as major differences between Asian PAEDs and those diagnosed in European/North American countries. The innovative molecular approaches, exploring driver mutations or new gene alterations, could help to identify rare prognostic factors and guide future tailored therapeutic approaches to this rare neoplasm.

show abstract

“…In addition, our current study and many other studies investigating racial and ethnic studies utilized self-reported methods based on physical features, culture heritage, traditions and geopolitical factors. These methods may not provide as accurate genomic information as genetic ancestry inferred using ancestry informative markers (AIM), particularly in admixture population ( 26 , 61 ). Further studies using AIM based characterization to investigate racial and ethnic studies is warranted.…”

Section: Discussionmentioning

confidence: 99%

“…Similarly, studies analyzing Lung Cancer Mutation Consortium (LCMC) also compared genetic alterations among different ethnic groups ( 1 , 18 , 20 , 24 , 25 ). Minority groups like African Americans are often under-represented in these relevant studies ( 26 ). For example, a total of 66 African Americans were included in the LCMC analysis, and the molecular targets primarily focused on ten oncogenic drivers.…”

Section: Introductionmentioning

confidence: 99%

Genomic landscape of lung adenocarcinomas in different races

et al. 2022

View full text Add to dashboard Cite

BackgroundLung adenocarcinoma is a molecularly heterogeneous disease. Several studies, including The Cancer Genome Atlas Research Network (TCGA) and Lung Cancer Mutation Consortium (LCMC), explored the genetic alterations among different ethnic groups. However, minority groups are often under-represented in these relevant studies and the genomic alterations among racial groups are not fully understood.MethodsWe analyze genomic characteristics among racial groups to understand the diversities and their impact on clinical outcomes.ResultsNative Americans had significantly higher rates of insertions and deletions than other races (P<0.001). Among patients with lung adenocarcinomas, EGFR and KRAS were the highest discrepancy genes in the different racial groups (P<0.001). The EGFR exon 21 L858R point mutation was three times higher in Asians than in all other races (P<0.001). Asians, Whites, and Blacks had 4.7%, 3.1%, and 1.8% ALK rearrangement, respectively (P<0.001). White patients had the highest rates of reported KRAS G12C (15.51%) than other races (P<0.001). Whites (17.2%), Blacks (15.1%), and Other (15.7%) had higher rates of STK11 mutation than Asians (3.94%) (P<0.001). RET rearrangement and ERBB2 amplification were more common in Asian patients than in Other racial groups. Apart from point mutations, structural variations, and fusion genes, we identified a significant amount of copy number alterations in each race.ConclusionsThe tumor genomic landscape is significantly distinct in different races. This data would shed light on the understanding of molecular alterations and their impacts on clinical management in different lung cancer patients.

show abstract

Non-small cell lung cancer genomics around the globe: focus on ethnicity

Cited by 4 publications

References 9 publications

MicroRNA-545 targets ZEB2 to inhibit the development of non‑small cell lung cancer by inactivating Wnt/β-catenin pathway

MicroRNA-545 targets ZEB2 to inhibit the development of non‑small cell lung cancer by inactivating Wnt/β-catenin pathway

Pulmonary enteric adenocarcinoma: an overview

Genomic landscape of lung adenocarcinomas in different races

Contact Info

Product

Resources

About